X0306 4 2019-03-21 0 0001609351 Spark Therapeutics, Inc. ONCE 0001631248 High Katherine A C/O SPARK THERAPEUTICS, INC. 3737 MARKET STREET, SUITE 1300 PHILADELPHIA PA 19104 1 1 0 0 See Remarks Common Stock 2019-03-21 4 M 0 73249 3.45 A 287717 D Common Stock 2019-03-21 4 F 0 31653 113.25 D 256064 D Common Stock 2019-03-21 4 M 0 5840 68.45 A 261904 D Common Stock 2019-03-21 4 M 0 3 40.44 A 261907 D Common Stock 2019-03-21 4 M 0 64160 68.45 A 326067 D Common Stock 2019-03-21 4 F 0 49561 113.255 D 276506 D Common Stock 2019-03-21 4 M 0 21247 40.44 A 297753 D Common Stock 2019-03-21 4 F 0 25993 113.26 D 271760 D Common Stock 2019-03-21 4 M 0 15750 56.17 A 287510 D Common Stock 2019-03-21 4 F 0 11184 113.26 D 276326 D Common Stock 2019-03-21 4 M 0 7875 50.55 A 284201 D Common Stock 2019-03-21 4 F 0 5367 113.26 D 278834 D Stock Option (right to buy) 3.45 2019-03-21 4 M 0 73249 0.00 D 2024-07-02 Common Stock 73249 0 D Stock Option (right to buy) 68.45 2019-03-21 4 M 0 5840 0.00 D 2025-03-15 Common Stock 5840 64160 D Stock Option (right to buy) 40.44 2019-03-21 4 M 0 3 0.00 D 2026-01-04 Common Stock 3 54997 D Stock Option (right to buy) 68.45 2019-03-21 4 M 0 64160 0.00 D 2025-03-15 Common Stock 64160 0 D Stock Option (right to buy) 40.44 2019-03-21 4 M 0 41247 0.00 D 2026-01-04 Common Stock 41247 13750 D Stock Option (right to buy) 56.17 2019-03-21 4 M 0 15750 0.00 D 2027-01-17 Common Stock 15750 15750 D Stock Option (right to buy) 50.55 2019-03-21 4 M 0 7875 0.00 D 2028-01-17 Common Stock 7875 23625 D 25% vested on May 24, 2015, and the remainder vested in equal quarterly installments over the following three years. 25% vested March 16, 2016 and the remainder vested in equal quarterly installments over the following three years. 25% vested Jamuary 5, 2017 and the remainder vests in equal quarterly installments over the following three years. 25% vested January 18, 2018 and the remainder vests in equal quarterly installments over the following three years. 25% vested January 18, 2019 and the remainder vests in equal annual installments over the following three years. President and Head of Research and Development /s/ Joseph W. La Barge, attorney-in-fact for Katherine A. High 2019-03-25